SIRT2 expression exhibits potential to serve as a biomarker for disease surveillance and prognosis in the management of cervical cancer patients.

Szczegóły
Abstrakt

Tytuł:: SIRT2 expression exhibits potential to serve as a biomarker for disease surveillance and prognosis in the management of cervical cancer patients.
Autorzy:: Yang LP; Department of Gynaecology and Obstetrics.
Feng HQ; Department of Gynaecology and Obstetrics.
Ma JC; Department of Gynaecology and Obstetrics.
Wu H; Department of Gynaecology and Obstetrics.
Liu CR; Department of Gynaecology and Obstetrics.
Hou JD; Department of Anesthesiology, HanDan Central Hospital, Handan 056008, China.
Źródło:: Medicine [Medicine (Baltimore)] 2020 Mar; Vol. 99 (11), pp. e18668.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins
MeSH Terms:: Sirtuin 2/*metabolism
Uterine Cervical Neoplasms/*diagnosis
Adult ; Biomarkers, Tumor/analysis ; Biomarkers, Tumor/metabolism ; Cervix Uteri/metabolism ; Disease-Free Survival ; Female ; Humans ; Middle Aged ; Prognosis ; Proportional Hazards Models ; Retrospective Studies ; Sirtuin 2/analysis ; Survival Analysis ; Uterine Cervical Neoplasms/metabolism ; Uterine Cervical Neoplasms/mortality
References:: Cell Rep. 2016 Oct 25;17(5):1302-1317. (PMID: 27783945)
Cochrane Database Syst Rev. 2014 Dec 03;(12):CD010401. (PMID: 25470408)
J Thorac Dis. 2018 Apr;10(4):2089-2099. (PMID: 29850112)
Lancet Infect Dis. 2015 May;15(5):565-80. (PMID: 25744474)
Nature. 2000 Feb 17;403(6771):795-800. (PMID: 10693811)
Vaccine. 2018 May 31;36(23):3381-3386. (PMID: 29735321)
Medicine (Baltimore). 2017 Apr;96(15):e6472. (PMID: 28403077)
Cell Death Dis. 2018 Dec 18;10(1):9. (PMID: 30584257)
Ir J Med Sci. 2020 Feb;189(1):83-89. (PMID: 31418154)
Eur J Cancer. 2014 Jan;50(2):290-301. (PMID: 24183459)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Clin Cancer Res. 2015 Jan 15;21(2):249-57. (PMID: 25421725)
Am Soc Clin Oncol Educ Book. 2015;:e299-309. (PMID: 25993189)
Mol Cell Proteomics. 2016 Oct;15(10):3107-3125. (PMID: 27503897)
Biochim Biophys Acta Mol Cell Res. 2018 Sep;1865(9):1230-1238. (PMID: 29908203)
Anticancer Res. 2012 Apr;32(4):1555-61. (PMID: 22493401)
Cell. 1999 Dec 23;99(7):735-45. (PMID: 10619427)
Science. 2000 Sep 22;289(5487):2126-8. (PMID: 11000115)
Oncotarget. 2016 Dec 6;7(49):80336-80349. (PMID: 27637077)
Mol Med Rep. 2017 Apr;15(4):1638-1646. (PMID: 28259910)
BMC Cancer. 2017 Dec 20;17(1):874. (PMID: 29262808)
Lancet. 2011 Jun 18;377(9783):2085-92. (PMID: 21684381)
Biochem Pharmacol. 2019 Apr;162:142-153. (PMID: 30352233)
Clin Lab. 2018 May 1;64(5):669-675. (PMID: 29739048)
Substance Nomenclature:: 0 (Biomarkers, Tumor)
EC 3.5.1.- (SIRT2 protein, human)
EC 3.5.1.- (Sirtuin 2)
Entry Date(s):: Date Created: 20200317 Date Completed: 20200323 Latest Revision: 20221005
Update Code:: 20240105
PubMed Central ID:: PMC7440089
DOI:: 10.1097/MD.0000000000018668
PMID:: 32176025
: Czasopismo naukowe

Full Text Finder

This study aimed to compare the sirtuin 2 (SIRT2) expression between tumor tissue and adjacent tissue, and to investigate the association of tumor SIRT2 expression with clinical characteristics and survival profiles in cervical cancer patients.One hundred ninety-one cervical cancer patients were reviewed in this retrospective study. All patients underwent surgical resection and had well-preserved tumor tissue and adjacent tissue, which were obtained for SIRT2 expression detection by immunohistochemistry (IHC). Clinical parameters were obtained. Disease free survival (DFS) and overall survival (OS) were calculated.Both SIRT2 expression by IHC score (P < .001) and the percentage of SIRT2 high expression (defined as IHC score >3) (P < .001) were declined in tumor tissue compared with paired adjacent tissue. In addition, SIRT2 expression in tumor tissue was negatively correlated with tumor size (P = .047), lymph node metastasis (P = .009) and FIGO stage (P = .001). And the DFS (P = .007) as well as OS (P = .008) were better in patients with SIRT2 high expression compared with patents with SIRT2 low expression. Univariate Cox's proportional hazards regression model analyses revealed that high SIRT2 expression in tumor tissue was a predictive factor for more prolonged DFS (P = .009) and OS (P = .011), while multivariate Cox's proportional hazards regression model analysis disclosed that it lacks independent predictive value for DFS (P = .084) or OS (P = .132).SIRT2 expression exhibits potential to serve as a biomarker for disease surveillance and prognosis in the management of cervical cancer patients.

Informacja